S&P Global
S&P Global’s valuation swung from 7x earnings in 2009 to 50x in 2024 as ratings, indices and proprietary data expanded through acquisitions and AI monetisation.
S&P Global’s valuation swung from 7x earnings in 2009 to 50x in 2024 as ratings, indices and proprietary data expanded through acquisitions and AI monetisation.
@yenoms You think $BX or anyone can take this one down?
I had to trim my $DJT short, it’s not moving down anymore with the rest of the market. Sad day.
$DIS making a comeback attempt from "fallen angel" status...
@challeyok You can go look at the GFC performance for $PSA The coverage ratio is 6.1x, will need NOI/EBITDA to fall over 80% before they have distribution issues
Bruce Flatt’s Brookfield built 19 percent annual returns by buying distressed real assets below replacement cost with long-term…
Forestar trades near $22 versus $37.56 in tangible book value, with $657 million of cash and a potential D.R.
Entravision’s AdTech revenue rose 133% and EBIT 261% in Q3 as management weighs TV-station sales before its TelevisaUnivision agreement…
LyondellBasell’s target falls to $75 from $80 as lower 2028 earnings, higher ethane costs and Chinese overcapacity outweigh its stronger…
Steve Eisman, Dan Ives and Gil Luria assess how the midterms could reshape AI data-center spending, Google search growth, and competition…
Reddit's search-traffic selloff overlooks that logged-in app users generate more than 80% of monetization, supporting a $130 one-year…
FactSet CEO Sanoke Viswanathan discusses using the firm’s client relationships and data platform to deploy AI across finance.
Accenture reported 6.5% FY26 revenue growth and $11.6 billion in free cash flow, while fixed-price contracts above 65% of bookings retain…
Adobe (ADBE) became a full position at about $246, backed by buybacks and confidence it can adapt to AI competition.
Sonida Senior Living owns 153 senior housing properties after a March 2026 merger doubled its scale, with aging-driven demand and tight…
BNTC · long Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.
NAIC oversight missed Delaware Life’s $13.34 billion affiliated-bond exposure and permits capital treatment that props up Brighthouse’s…
BPRE trades 45% below NAV as Saba and Bulldog press for buybacks or a manager change, challenging Bluerock’s incentive to preserve…
Hindsight Capital tests crisis-era investment decisions using anonymized company financials, including TransDigm, Halma and Texas Pacific…
Sezzle’s Q2 2026 revenue rose 51.7% and adjusted net income 58.4%, while revenue per GMV reached 11.7% as Premium subscriptions lifted…
Microsoft, Amazon, Oracle, Meta and Alphabet face another two years of record AI data-center investment amid $3 trillion in commitments,…
Intuit trades at historically low multiples as DIY tax pricing pressure and customer losses test its growth, while assisted tax, Money and…
Intel’s Panther Lake puts 18A PowerVia backside power and RibbonFET GAA transistors into commercial silicon, with logic density similar to…
Honeywell Aerospace, newly spun off as HONA, fell 41% from post-listing highs after Q2 2026 as supply-chain bottlenecks delayed revenue…
VersaBank uses cash holdbacks and put-backs to buy point-of-sale loan cash flows, with C$7 billion in assets and AI-enabled real-time…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.